We are live on ! Find out more
SOCM

SR One Capital Management Portfolio holdings

AUM $1.04B
1-Year Est. Return 262.99%
This Fund
S&P 500
This Quarter Est. Return
+38.77%
1 Year Est. Return
+262.99%
3 Year Est. Return
+655.88%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.04B
AUM Growth
+$124M
Cap. Flow
-$102M
Cap. Flow %
-9.81%
Top 10 Hldgs %
95.11%
Holding
17
New
3
Increased
1
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
AVLN
Avalyn Pharma
AVLN
+$95.5M
2
ODTX
Odyssey Therapeutics
ODTX
+$66.5M
3
MOBI
Mobia Medical
MOBI
+$25.7M
4
ORIC icon
Oric Pharmaceuticals
ORIC
+$911K

Top Sells

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$269M
2
ORKA
Oruka Therapeutics
ORKA
+$21.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MANE
1
Veradermics Inc
MANE
$4.87B
$295M 28.42%
2,401,868
– –
ZBIO
2
Zenas BioPharma
ZBIO
$1.76B
$128M 12.31%
5,037,854
– –
CRSP icon
3
CRISPR Therapeutics
CRSP
$5.24B
$111M 10.7%
2,038,763
– –
AVLN
4
Avalyn Pharma
AVLN
$1.24B
$109M 10.48%
+3,308,649
New +$95.5M
DSGN icon
5
Design Therapeutics
DSGN
$758M
$94.4M 9.09%
6,526,476
– –
ODTX
6
Odyssey Therapeutics
ODTX
$986M
$71M 6.83%
+3,794,883
New +$66.5M
ALMS
7
Alumis Inc
ALMS
$919M
$55.2M 5.31%
1,959,896
– –
ORIC icon
8
Oric Pharmaceuticals
ORIC
$1.36B
$50M 4.81%
4,615,384
+100,455
+2% +$911K
MLYS icon
9
Mineralys Therapeutics
MLYS
$2.29B
$42.2M 4.06%
1,563,966
– –
SPRY icon
10
ARS Pharmaceuticals
SPRY
$406M
$32.1M 3.09%
4,012,903
– –
MOBI
11
Mobia Medical
MOBI
$302M
$26.6M 2.56%
+1,986,072
New +$25.7M
NKTX icon
12
Nkarta
NKTX
$197M
$9.43M 0.91%
3,333,333
– –
OCS icon
13
Oculis Holding
OCS
$515M
$8.89M 0.86%
641,022
– –
RARE icon
14
Ultragenyx Pharmaceutical
RARE
$1.43B
$4.6M 0.44%
137,753
– –
ENGN icon
15
enGene Therapeutics
ENGN
$131M
$1.29M 0.12%
747,750
– –
ACLX
16
DELISTED
Arcellx
ACLX
– –
-2,346,630
Closed -$269M
ORKA
17
Oruka Therapeutics
ORKA
$5.59B
– –
-430,330
Closed -$21.1M

Similar funds

HTIM
Harbour Trust & Investment Management Michigan City, Indiana $1.04B AUM 29.41% 1-Year Est. Return
USGIU
U.S. Global Investors (USGI) San Antonio, Texas $1.04B AUM 73.31% 1-Year Est. Return
WC
Westerkirk Capital Victoria $1.04B AUM 28.18% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $1.04B AUM 24.74% 1-Year Est. Return
LPC
Long Pond Capital New York $1.04B AUM 2.38% 1-Year Est. Return
OMG
One Madison Group New York $1.04B AUM 25.35% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $1.04B AUM 52.56% 1-Year Est. Return
GKFF
George Kaiser Family Foundation Tulsa, Oklahoma $1.04B AUM 36.93% 1-Year Est. Return

SR One Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, SR One Capital Management held 17 positions worth $1.04B, up 13% from $915M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

SR One Capital Management withdrew a net $102M in Q2 2026, closing 2 positions. Its most notable exit was Arcellx, an estimated $269M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, SR One Capital Management opened a new position in Avalyn Pharma worth $109M.

  • SR One Capital Management's largest Q2 2026 buy was Avalyn Pharma: 3,308,649 shares worth $109M.
  • SR One Capital Management added most to Oric Pharmaceuticals in Q2 2026, an estimated $911K increase.
  • SR One Capital Management fully exited Arcellx in Q2 2026, selling an estimated $269M.
  • SR One Capital Management's ten largest holdings make up 95% of its $1.04B portfolio in Q2 2026.
  • SR One Capital Management opened 3 new positions and closed 2 in Q2 2026.
  • SR One Capital Management's portfolio value rose 13% quarter-over-quarter to $1.04B.

Based on SR One Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.